Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment under draft NICE guidance published today.

Evidence-based recommendations on dostarlimab (Jemperli) for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.

NICE is unable to make a recommendation on brensocatib (Brinsupri) for treating non-cystic fibrosis bronchiectasis in people 12 years and over. This is because the company did not provide an evidence ...